Anti-murine RANKL antibody used for in-vivo research by The Walter and Eliza Hall Institute of Medical Research, Australia

Toyko, Japan – Oriental Yeast Company, OYC Americas’ parent company, is pleased to announce its anti-murine RANKL monoclonal antibody was used in the study “Control of mammary stem cell function by hormone signaling” that was published by Nature, the international weekly journal of science.

Anti-murine RANKL monoclonal antibody was developed by OYC’s Nagahama Institute for Biomedical Sciences. Receptor activator of NF-kB ligand (RANKL), also designated TRANCE, OPGL and ODF, is a member of the TNF family that is expressed in osteoblasts, activated T cells. RANKL interacts with its receptor RANK expressed on osteoclast progenitors and mature dendritic cells, leading to osteoclastogenesis and T cell proliferation, respectively.

To read more the research paper “Control of mammary stem cell function by hormone signaling”, please visit the Nature website or go directly to the abstract:

Find our more about OYC’s Life Science Research and our anti-murine RANKL Monoclonal Antibody.

For additional information, please contact OYC Americas at 760-659-5943 or email Sattan Acharya (

This entry was posted in Press Releases. Bookmark the permalink.